These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 38748805)

  • 1. Precise modulation and use of reactive oxygen species for immunotherapy.
    Li X; Gao J; Wu C; Wang C; Zhang R; He J; Xia ZJ; Joshi N; Karp JM; Kuai R
    Sci Adv; 2024 May; 10(20):eadl0479. PubMed ID: 38748805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improving Vaccine and Immunotherapy Design Using Biomaterials.
    Bookstaver ML; Tsai SJ; Bromberg JS; Jewell CM
    Trends Immunol; 2018 Feb; 39(2):135-150. PubMed ID: 29249461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reactive oxygen species (ROS)-responsive biomaterials mediate tissue microenvironments and tissue regeneration.
    Yao Y; Zhang H; Wang Z; Ding J; Wang S; Huang B; Ke S; Gao C
    J Mater Chem B; 2019 Aug; 7(33):5019-5037. PubMed ID: 31432870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delivery strategies of cancer immunotherapy: recent advances and future perspectives.
    Zhao Z; Zheng L; Chen W; Weng W; Song J; Ji J
    J Hematol Oncol; 2019 Nov; 12(1):126. PubMed ID: 31779642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advances in immunotherapy delivery from implantable and injectable biomaterials.
    Leach DG; Young S; Hartgerink JD
    Acta Biomater; 2019 Apr; 88():15-31. PubMed ID: 30771535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomaterial-based platforms for in situ dendritic cell programming and their use in antitumor immunotherapy.
    Calmeiro J; Carrascal M; Gomes C; Falcão A; Cruz MT; Neves BM
    J Immunother Cancer; 2019 Sep; 7(1):238. PubMed ID: 31484548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgery-free injectable macroscale biomaterials for local cancer immunotherapy.
    Lei K; Tang L
    Biomater Sci; 2019 Feb; 7(3):733-749. PubMed ID: 30637428
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy.
    Ni K; Luo T; Nash GT; Lin W
    Acc Chem Res; 2020 Sep; 53(9):1739-1748. PubMed ID: 32808760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Advances in Stimuli-Responsive Platforms for Cancer Immunotherapy.
    Li L; Yang Z; Chen X
    Acc Chem Res; 2020 Oct; 53(10):2044-2054. PubMed ID: 32877161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advanced Biomaterials for Cell-Specific Modulation and Restore of Cancer Immunotherapy.
    Ruan S; Huang Y; He M; Gao H
    Adv Sci (Weinh); 2022 May; 9(16):e2200027. PubMed ID: 35343112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ROS-Responsive Biomaterial Design for Medical Applications.
    Lee JB; Shin YM; Kim WS; Kim SY; Sung HJ
    Adv Exp Med Biol; 2018; 1064():237-251. PubMed ID: 30471037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Local biomaterials-assisted cancer immunotherapy to trigger systemic antitumor responses.
    Chen Q; Chen M; Liu Z
    Chem Soc Rev; 2019 Nov; 48(22):5506-5526. PubMed ID: 31589233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Self-Assembly as a Molecular Strategy to Improve Immunotherapy.
    Froimchuk E; Carey ST; Edwards C; Jewell CM
    Acc Chem Res; 2020 Nov; 53(11):2534-2545. PubMed ID: 33074649
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the clinical impact of biomaterials in cancer immunotherapy.
    Gammon JM; Dold NM; Jewell CM
    Oncotarget; 2016 Mar; 7(13):15421-43. PubMed ID: 26871948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current progress in Reactive Oxygen Species (ROS)-Responsive materials for biomedical applications.
    Lee SH; Gupta MK; Bang JB; Bae H; Sung HJ
    Adv Healthc Mater; 2013; 2(6):908-15. PubMed ID: 25136729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Harnessing immune response using reactive oxygen Species-Generating/Eliminating inorganic biomaterials for disease treatment.
    Zhao C; Deng H; Chen X
    Adv Drug Deliv Rev; 2022 Sep; 188():114456. PubMed ID: 35843505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactive oxygen species-powered cancer immunotherapy: Current status and challenges.
    He M; Wang M; Xu T; Zhang M; Dai H; Wang C; Ding D; Zhong Z
    J Control Release; 2023 Apr; 356():623-648. PubMed ID: 36868519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Controlled release of immunotherapeutics for enhanced cancer immunotherapy after local delivery.
    Jin Q; Liu Z; Chen Q
    J Control Release; 2021 Jan; 329():882-893. PubMed ID: 33053396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomaterial-based platforms for modulating immune components against cancer and cancer stem cells.
    Desai N; Hasan U; K J; Mani R; Chauhan M; Basu SM; Giri J
    Acta Biomater; 2023 Apr; 161():1-36. PubMed ID: 36907233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Critical role of the gut microbiota in immune responses and cancer immunotherapy.
    Li Z; Xiong W; Liang Z; Wang J; Zeng Z; Kołat D; Li X; Zhou D; Xu X; Zhao L
    J Hematol Oncol; 2024 May; 17(1):33. PubMed ID: 38745196
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.